Market Prospect of Hesperidin

1. Brief Introduction

ABOUT SHUXI

Chengdu Pujiang Shuxi Plant Biochemical Co., Ltd., our first factory, was established in 1995 and dedicated in manufacturing Hesperidin. In March of 2008, our another factory, Chengdu Shuxi Pharmaceutical Co., Ltd., was founded covering an area of 60,000 square meters and producing natural plant extracts, intermediates and APIs. We have been in the line of manufacturing and marketing Hesperidin for about 22 years, and we have been a very important supplier of Hesperidin worldwide. Till now, we have distributed our products to many countries and regions all over the world.

After decades of endeavor, we now have equipped with advanced manufacturing facilities, testing equipment, production process, as well as a strict quality control system conforming to international standards, so that we can meet all the demands of our customers in terms of product specification and quality. Meanwhile, we invest most of our revenue in R&D and facilities upgrading for providing a more comprehensive solution to our customers and cultivating an energy-saving and environmental-friendly production mode.

Based on the efforts we made in the past, we will always try to better our customer service and create the greatest value for our customers. We believe, via hardworking, we can make our contribution to the health undertaking of humankind.

2. Market Prospect

The soaring of Hesperidin production recent years contributes mainly to the rapid growth in pharmaceutical industry in Europe and America. It creates increasing demand for Hesperidin. Apart from overseas market, domestic market also boosts very quickly, thanks to the development of pharmaceutical industry.

Nowadays, Hesperidin has been more and more used in the medicine for the treatment of high blood pressure and myocardial infarction, which is in great demand with an increasing scale. Therefore, Hesperidin production would be prospering in the next a few years.

In 2015, global yield of Hesperidin is 6,882 tons, and 83% of it comes from Chinese producers. QYResearch, a professional researcher in China, predicts that global demand for Hesperidin will reach 9,543 tons by 2021.

As the prosperity of Hesperidin industry, higher added value gives manufacturers impetus to produce Diosmin. With vitamin P-like effect, Diosmin can not only reduce the vascular fragility and abnormal permeability, but also prevent hypertension and assist medical intervention of arteriosclerosis. Besides, it’s also used in the treatment of capillary fragility. The popularity of the use of Diosmin is attributed to its characteristics of low toxicity. It has great potential in clinic application and market.

3. Factory Overview

Our two factories are all located in Pujiang county, Chengdu, Sichuan province, China. Annual production capacity of Hesperidin is 1500 tons, and 300 tons of Diosmin. Our products are Hesperidin (extract by water), Hesperidin (extract by methanol), Hesperidin (extract by ethanol), Diosmin (powder), Diosmin (granular), Diosmin:Hesperidin (9:1), Hesperidin Methyl Chalcone, Naringin, Neohesperidin, Neohesperidin Dihydrochalcone, PMFs etc.